Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy (original) (raw)

• Pinyol M, Bea S, Pla L, Ribrag V, Bosq J, Rosenwald A et al. Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. Blood 2007; 109: 5422–5429.
  Article CAS PubMed Google Scholar
• Zelenetz AD . Mantle cell lymphoma: an update on management. Ann Oncol 2006; 17 (Suppl 4): iv12–iv14.
  Article PubMed Google Scholar
• Martin P, Leonard JP . Novel therapeutic targets in mantle cell lymphoma. Expert Opin Ther Targets 2007; 11: 929–940.
  Article CAS PubMed Google Scholar
• Evens AM, Winter JN, Hou N, Nelson BP, Rademaker A, Patton D et al. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. Br J Haematol 2008; 140: 385–393.
  Article CAS PubMed Google Scholar
• Bertoni F, Ponzoni M . The cellular origin of mantle cell lymphoma. Int J Biochem Cell Biol 2007; 39: 1747–1753.
  Article CAS PubMed Google Scholar
• Campo E, Raffeld M, Jaffe ES . Mantle-cell lymphoma. Semin Hematol 1999; 36: 115–127.
  CAS PubMed Google Scholar
• June CH . Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117: 1466–1476.
  Article CAS PubMed PubMed Central Google Scholar
• Osterroth F, Garbe A, Fisch P, Veelken H . Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells. Blood 2000; 95: 1342–1349.
  CAS PubMed Google Scholar
• Schultze JL, Seamon MJ, Michalak S, Gribben JG, Nadler LM . Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood 1997; 89: 3806–3816.
  CAS PubMed Google Scholar
• Wen YJ, Barlogie B, Yi Q . Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 2001; 97: 1750–1755.
  Article CAS PubMed Google Scholar
• Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R . Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992; 327: 1209–1215.
  Article CAS PubMed Google Scholar
• Franki SN, Steward KK, Betting DJ, Kafi K, Yamada RE, Timmerman JM . Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo. Blood 2008; 111: 1504–1511.
  Article CAS PubMed PubMed Central Google Scholar
• Fernandez V, Hartmann E, Ott G, Campo E, Rosenwald A . Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005; 23: 6364–6369.
  Article CAS PubMed Google Scholar
• Amin HM, McDonnell TJ, Medeiros LJ, Rassidakis GZ, Leventaki V, O’Connor SL et al. Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med 2003; 127: 424–431.
  PubMed Google Scholar
• Jares P, Colomer D, Campo E . Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007; 7: 750–762.
  Article CAS PubMed Google Scholar
• Klier M, Anastasov N, Hermann A, Meindl T, Angermeier D, Raffeld M et al. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 2008; 22: 2097–2105.
  Article CAS PubMed Google Scholar
• Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996; 196: 137–151.
  Article CAS PubMed Google Scholar
• Sallusto F, Lanzavecchia A . Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109–1118.
  Article CAS PubMed Google Scholar
• Anton D, Dabadghao S, Palucka K, Holm G, Yi Q . Generation of dendritic cells from peripheral blood adherent cells in medium with human serum. Scand J Immunol 1998; 47: 116–121.
  Article CAS PubMed Google Scholar
• Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D’Amaro J et al. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 1993; 23: 1215–1219.
  Article CAS PubMed Google Scholar
• Qian J, Xie J, Hong S, Yang J, Zhang L, Han X et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 2007; 110: 1587–1594.
  Article CAS PubMed PubMed Central Google Scholar
• Qian J, Wang S, Yang J, Xie J, Lin P, Freeman ME et al. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96. Clin Cancer Res 2005; 11: 8808–8815.
  Article CAS PubMed Google Scholar
• Fulcher D, Wong S . Carboxyfluorescein succinimidyl ester-based proliferative assays for assessment of T cell function in the diagnostic laboratory. Immunol Cell Biol 1999; 77: 559–564.
  Article CAS PubMed Google Scholar
• Yi Q, Bergenbrant S, Osterborg A, Osby E, Ostman R, Bjorkholm M et al. T-cell stimulation induced by idiotypes on monoclonal immunoglobulins in patients with monoclonal gammopathies. Scand J Immunol 1993; 38: 529–534.
  Article CAS PubMed Google Scholar
• Yi Q, Osterborg A, Bergenbrant S, Mellstedt H, Holm G, Lefvert AK . Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 1995; 86: 3043–3049.
  CAS PubMed Google Scholar
• Tourdot S, Scardino A, Saloustrou E, Gross DA, Pascolo S, Cordopatis P et al. A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol 2000; 30: 3411–3421.
  Article CAS PubMed Google Scholar
• Chen JL, Dunbar PR, Gileadi U, Jager E, Gnjatic S, Nagata Y et al. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol 2000; 165: 948–955.
  Article CAS PubMed Google Scholar
• Tsomides TJ, Walker BD, Eisen HN . An optimal viral peptide recognized by CD8+ T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. Proc Natl Acad Sci USA 1991; 88: 11276–11280.
  Article CAS PubMed PubMed Central Google Scholar
• Dyall J, Latouche JB, Schnell S, Sadelain M . Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood 2001; 97: 114–121.
  Article CAS PubMed Google Scholar
• de Jong R, Brouwer M, Miedema F, van Lier RA . Human CD8+ T lymphocytes can be divided into CD45RA+ and CD45RO+ cells with different requirements for activation and differentiation. J Immunol 1991; 146: 2088–2094.
  CAS PubMed Google Scholar
• Cobb BS, Hertweck A, Smith J, O’Connor E, Graf D, Cook T et al. A role for Dicer in immune regulation. J Exp Med 2006; 203: 2519–2527.
  Article CAS PubMed PubMed Central Google Scholar
• Woodland DL, Dutton RW . Heterogeneity of CD4(+) and CD8(+) T cells. Curr Opin Immunol 2003; 15: 336–342.
  Article CAS PubMed Google Scholar
• Pulendran B, Dillon S, Joseph C, Curiel T, Banchereau J, Mohamadzadeh M . Dendritic cells generated in the presence of GM-CSF plus IL-15 prime potent CD8+ Tc1 responses in vivo. Eur J Immunol 2004; 34: 66–73.
  Article CAS PubMed Google Scholar
• Zhang Y, Renkvist N, Sun Z, Schuler-Thurner B, Glaichenhaus N, Schuler G et al. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells. Eur J Immunol 2005; 35: 1066–1075.
  Article CAS PubMed Google Scholar
• Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004; 113: 1515–1525.
  Article CAS PubMed PubMed Central Google Scholar
• Vonderheide RH, Hahn WC, Schultze JL, Nadler LM . The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10: 673–679.
  Article CAS PubMed Google Scholar
• Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, Nadler LM . Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res 2001; 7: 3343–3348.
  CAS PubMed Google Scholar
• Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D et al. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 2000; 60: 4845–4849.
  CAS PubMed Google Scholar
• Andersen MH, Pedersen LO, Becker JC, Straten PT . Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 2001; 61: 869–872.
  CAS PubMed Google Scholar
• Pisarev V, Yu B, Salup R, Sherman S, Altieri DC, Gabrilovich DI . Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res 2003; 9: 6523–6533.
  CAS PubMed Google Scholar
• Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 2004b; 113: 425–433.
  Article CAS PubMed PubMed Central Google Scholar
• Kuriyama H, Shimizu K, Lee W, Kjaergaard J, Parkhurst MR, Cohen PA et al. Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells. Dev Biol (Basel) 2004; 116: 169–178; discussion 179–186.
  CAS Google Scholar
• Otto K, Andersen MH, Eggert A, Keikavoussi P, Pedersen LO, Rath JC et al. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 2005; 23: 884–889.
  Article CAS PubMed Google Scholar
• Marzec M, Kasprzycka M, Lai R, Gladden AB, Wlodarski P, Tomczak E et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 2006; 108: 1744–1750.
  Article CAS PubMed PubMed Central Google Scholar
• Witzig TE . Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 2005; 23: 6409–6414.
  Article CAS PubMed Google Scholar
• Quelle DE, Ashmun RA, Shurtleff SA, Kato JY, Bar-Sagi D, Roussel MF et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 1993; 7: 1559–1571.
  Article CAS PubMed Google Scholar
• Lu XL, Jiang XB, Liu RE, Zhang FC, Zhao HY . Generation of allo-restricted cytotoxic T lymphocytes against malignant glioma by artificial antigen-presenting cells. Cancer Lett 2007; 256: 128–135.
  Article CAS PubMed Google Scholar
• Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927–1932.
  CAS PubMed Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833.
  Article CAS PubMed Google Scholar